EPS for Aileron Therapeutics, Inc. (ALRN) Expected At $-0.46

January 20, 2018 - By Migdalia James

 EPS for Aileron Therapeutics, Inc. (ALRN) Expected At $ 0.46

Analysts expect Aileron Therapeutics, Inc. (NASDAQ:ALRN) to report $-0.46 EPS on February, 8.After having $-0.43 EPS previously, Aileron Therapeutics, Inc.’s analysts see 6.98 % EPS growth. The stock decreased 4.26% or $0.41 during the last trading session, reaching $9.21. About 36,697 shares traded or 35.64% up from the average. Aileron Therapeutics, Inc. (NASDAQ:ALRN) has 0.00% since January 20, 2017 and is . It has underperformed by 16.70% the S&P500.

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing a novel class of therapeutics in the United States. The company has market cap of $135.56 million. The company??s lead product includes ALRN-6924, a stapled peptide that in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial for the treatment of peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia and advanced myelodysplastic syndrome (MDS); and Phase II b trial for the treatment of AML/MDS in combination with cytosine arabinoside. It currently has negative earnings. It is also developing next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors.

More notable recent Aileron Therapeutics, Inc. (NASDAQ:ALRN) news were published by: Globenewswire.com which released: “Aileron Therapeutics Reports Second Quarter 2017 Financial Results” on August 10, 2017, also Globenewswire.com with their article: “Aileron Therapeutics Added to the Russell 2000, Russell 3000 and Russell …” published on September 19, 2017, Businesswire.com published: “Aileron Therapeutics Announces Oral Presentation at ASCO on ALRN-6924 …” on May 18, 2017. More interesting news about Aileron Therapeutics, Inc. (NASDAQ:ALRN) were released by: Seekingalpha.com and their article: “Biopharm Aileron Therapeutics’ IPO Set For Thursday: We’re Cautious” published on June 27, 2017 as well as Nasdaq.com‘s news article titled: “Cancer biotech Aileron Therapeutics sets terms for $60 million IPO” with publication date: June 19, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: